Expression and purification of the Lipl41, a surface-exposed lipoprotein antigen of pathogenic *Leptospira* spp.

Narges Golab¹, Pejvak Khaki²*, Naser Harzandi¹, Majid Esmaelizad³, and Majid Tebianian⁴

¹Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran
²Department of Microbiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
³Department of Biotechnology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
⁴Department of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran

**ABSTRACT**

Pathogenic species of *Leptospira* lead to a zoonotic disease called leptospirosis, which is spread worldwide. A major topic of investigation is to detect the antigens that induce an immune response and to utilize them in diagnostic kits or vaccine development. The outer membrane proteins (*OMPs*) of *Leptospira* are potential candidates for this purpose. Lipl41 is an *OMP* that is conserved among pathogenic *Leptospira*. The aim of this study was to express and purify the Lipl41 recombinant protein in Iranian isolates. All collected Lipl41 protein sequences were compared and analyzed using bioinformatics tools from NCBI databases. Complete codon sequences of the Iranian pattern of Lipl41 recombinant protein were codon optimized and sub-cloned into a pET32a+ expression vector, and transformed into *Escherichia coli* BL21 (DE3). Optimal expression of recombinant Lipl41 (47kDa) was achieved post-induction with IPTG within the inclusion body. It was then purified by denaturation using serial concentrations of urea, and the recombinant protein was confirmed by western blot. In this study, sufficient amounts of Lipl41 were expressed and purified to be used for the development of a diagnostic kit and subunit vaccine.

**Key words:** recombinant protein Lipl41; expression; purification; pathogenic *Leptospira*

---

*Corresponding author:
Assoc. Prof. Pejvak Khaki, PhD, Head of Department of Microbiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran, Phone: +98 263 457 0038-46; Fax: +98 2634 552 194; E-mail: P.khaki@rvsri.ac.ir; Khakipejvak53@gmail.com

---

Expression and purification of the Lipl41, a surface-exposed lipoprotein antigen of pathogenic *Leptospira* spp. is a global zoonotic disease caused by pathogenic *Leptospira*. It is regularly prevalent in tropical, subtropical and humid parts with high levels of rainfall (ADLER and MOCTEZUMA, 2010), mostly in poor urban areas in developing countries (LOMAR et al., 2000). The clinical syndromes in humans are difficult to differentiate. The manifestations can range from a moderate fever similar to flu, to more serious illnesses presenting with hemorrhage, jaundice, myalgia,
renal dysfunction, and aseptic meningitis, which can lead to death in some patients (SEIJO et al., 2002; KHAKI, 2016a). After infection, *Leptospira* can colonize the renal tubules of a number of wild and domestic animals for prolonged periods, and are discharged through urine into the environment (BURRIEL et al., 2003; MONAHAHAN et al., 2008). Humans are usually contaminated directly or indirectly by infected animal urine. (MCBRIDE et al., 2005; INANLOU et al., 2015). Due to the widespread animal reservoirs, eradication of leptospirosis is problematic (ZAKERI et al., 2010). Despite vaccination, the disease still survives (KOIZUMI and WATANABE, 2005). Although vaccine development is the main strategy to remove the illness, current drawbacks of whole-cell vaccines include short duration of immunity, serovar specificity and side effects (VEDHAGIRI et al., 2009; LIN et al., 2016). Thus, the production of an efficient vaccine with lower levels of toxicity is essential to control and eliminate this disease (DELLAGOSTIN et al., 2011). Many studies on the development of recombinant vaccines against leptospirosis have used conserved outer membrane proteins (*OMPs*) such as Lipl21, Lipl32, Lipl41, Ompl1, etc (VEDHAGIRI et al., 2009; MEGUDESWARAN et al., 2014; LIN et al., 2016; CHANDY et al., 2017). OMPs revealed on the surface are among the most impressive antigens that can affect immune responses throughout the course of the disease. (FLANNERY et al., 2001; OLIVEIRA et al., 2015). There are three classes of leptospiral OM proteins (*OMPs*) which consist of lipoproteins, trans membrane proteins and peripheral membrane proteins (SHANG et al., 1996; ADLER et al., 2011). Regarding abundance, Lipl41 (41kDa) is the third among OM lipoproteins (CULLEN et al., 2005). This protein is an immunogenic antigen and expressed only in the pathogenic *Leptospira*, but notably absent in nonpathogenic species (KHAKI et al., 2016b), and has been considered as an indicator in serodiagnosis of the disease (HAAKE et al., 1999; MARIYA et al., 2006). Results of earlier studies have also shown that Lipl41 is surface exposed and expressed during infection in mammalian hosts (SENTHILKUMAR et al., 2007; KING et el., 2013). Therefore, it may be considered a potential subunit vaccine candidate against leptospirosis and, moreover, could be useful in a diagnostic kit. (SRIVASTAVA, 2006; SRIKRAM et al., 2011). Hence, in this present study, our aim was to express and purify Iranian isolates of the Lipl41 r protein of pathogenic *Leptospira* to develop a recombinant antigen.

**Materials and methods**

**Bioinformatics studies and generation of Lipl41 construct.** Twenty-seven complete coding sequences of Lipl41 protein 1065bp (355aa) from six prevalent pathogenic *Leptospira* serovars, consisting of eleven from Iran, such as: serovar Canicola, serovar Autumnalis, serovar Hardjo, serovar Icterohaemorrhagiae, serovar Pomona, serovar Grippotyphosa, and sixteen lipl41 sequences from other countries available in NCBI database were collected from GenBank (https://www.ncbi.nlm.nih.gov/GenBank) by using the BLAST online software (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Table 1). All collected protein sequences were compared and analyzed using bioinformatics tools such as MegAlign software.

A partial sequence of Lipl41, including coding sequences of amino acids number 21 to 355 (1005 bp) minus signal peptide (first 20aa), was synthesized by General Biosystems, Inc, USA. In addition, pET-32a+ was used to produce a 47kDa TRX-Lipl41 fusion protein. EcoR I- Sal I restriction sites were used for sub cloning into the pET-32a+ vector and the His-Tag sequence was considered for affinity purification. Codon optimization of Lipl41 was carried out for better expression in *Escherichia coli* with pET32a+ expression vector.

**Expression.** The recombinant plasmid of pET32a-Lipl41 was transformed into *E. coli* BL21 (DE3) as the host strain, on LB Agar containing 50 μg/mL ampicillin by the heat shock method (SAMBROOK and RUSSEL, 2001). Then a matrix plate was subcultured, and one single colony of it was cultured in 5 mL LB broth medium, supplemented with 5 μg/mL Aμmpicillin at 37 °C overnight. One mL of this suspension was inoculated onto 50 mL 2YT/AMP broth medium for induction. When the optical density reached 0.6 A_{600}, the recombinant plasmid was induced with Isopropyl- β-D-Thio Galacto
Pyranoside (IPTG). Sampling was performed before and after induction at different times (0 - 4 h and also 16 h). Different incubation temperatures (22 and 37 °C) and various concentrations (0.1 to 0.5mM) of IPTG were analyzed. The induced cells were harvested by centrifuge at 5000 g at 4 °C for 5 min. The pellets were suspended in 1XPBS (137 mMNaCl, 2 mM K2HPO4, 10 mM Na2HPO4, 2.7 mM KCl, pH 7.4) with sample buffer added (5× solution of 250 mM Tris.HCl, pH 6.8, 10% SDS, 30% (v/v) Glycerol, 10 mM DTT, 0.05% (w/v) bromophenol blue, 2-Mercaptoethanol), boiled for 5 min, then analyzed by SDS-PAGE using a 10% polyacrylamide gel along with Unstained protein markers (Thermo Scientific, USA). The gel was stained for 2 hr by standard Coomassie brilliant blue R-250 and destained with 45% methanol, 10% acetic acid glacial solution. Induced cells were resuspended in PBS with 10mM imidazole, and sonicated five times for 1 minute on ice with one minute intervals. After that, Phenyl Methyl Sulfonyl Fluoride (PMSF) was added to inhibit protease activity. The cell lysate was centrifuged at 15,000 g at 4 °C for 15 min. The supernatant and pellet analyzed by SDS-PAGE.

Table 1. List of LipL41 sequences of Leptospira interrogans used in this study

<table>
<thead>
<tr>
<th>Protein Id</th>
<th>Serovar</th>
<th>Strain</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAT48499.1</td>
<td>Australis</td>
<td>65-9</td>
<td>China</td>
</tr>
<tr>
<td>BAE48274.1</td>
<td>Australis</td>
<td>Akiyami C</td>
<td>Japan</td>
</tr>
<tr>
<td>AAV88037.1</td>
<td>Australis</td>
<td>65-9</td>
<td>China</td>
</tr>
<tr>
<td>AHW80383.1</td>
<td>Autumnalis</td>
<td>RTCC2802</td>
<td>Iran</td>
</tr>
<tr>
<td>AAT48498.1</td>
<td>Autumnalis</td>
<td>Lin 4</td>
<td>China</td>
</tr>
<tr>
<td>BAE48272.1</td>
<td>Autumnalis</td>
<td>Akiyami A</td>
<td>Japan</td>
</tr>
<tr>
<td>AHW80387.1</td>
<td>Canicola</td>
<td>RTCC2824</td>
<td>Iran</td>
</tr>
<tr>
<td>AAT48495.1</td>
<td>Canicola</td>
<td>Lin</td>
<td>China</td>
</tr>
<tr>
<td>AHX26958.1</td>
<td>Canicola</td>
<td>RTCC2805</td>
<td>Iran</td>
</tr>
<tr>
<td>AAT65971.1</td>
<td>Canicola</td>
<td>----------</td>
<td>India</td>
</tr>
<tr>
<td>AHW80384.1</td>
<td>Hardjo</td>
<td>RTCC2810</td>
<td>Iran</td>
</tr>
<tr>
<td>AAT65970.1</td>
<td>Hardjo</td>
<td>----------</td>
<td>India</td>
</tr>
<tr>
<td>AHX26962.1</td>
<td>Hardjo</td>
<td>RTCC 2821</td>
<td>Iran</td>
</tr>
<tr>
<td>AHW80386.1</td>
<td>Icterohaemorrhagiae</td>
<td>RTCC2823</td>
<td>Iran</td>
</tr>
<tr>
<td>AHX26960.1</td>
<td>Icterohaemorrhagiae</td>
<td>RTCC2812</td>
<td>Iran</td>
</tr>
<tr>
<td>ACV53831.1</td>
<td>Icterohaemorrhagiae</td>
<td>----------</td>
<td>India</td>
</tr>
<tr>
<td>AAS21814.1</td>
<td>Kremastos</td>
<td>Kremastos</td>
<td>USA</td>
</tr>
<tr>
<td>AHW80385.1</td>
<td>Pomona</td>
<td>RTCC2822</td>
<td>Iran</td>
</tr>
<tr>
<td>AHX26961.1</td>
<td>Pomona</td>
<td>RTCC 2815</td>
<td>Iran</td>
</tr>
<tr>
<td>AAU04601.1</td>
<td>Pomona</td>
<td>Luo</td>
<td>China</td>
</tr>
<tr>
<td>AAV88038.1</td>
<td>Pomona</td>
<td>Luo</td>
<td>China</td>
</tr>
<tr>
<td>AAS21818.1</td>
<td>Pomona</td>
<td>PomonaRZ11</td>
<td>USA</td>
</tr>
<tr>
<td>AHA11954.1</td>
<td>Pomona</td>
<td>Pomona P</td>
<td>Argentina</td>
</tr>
<tr>
<td>AHW80388.1</td>
<td>Grippotyphosa</td>
<td>RTCC2825</td>
<td>Iran</td>
</tr>
<tr>
<td>AFH54361.1</td>
<td>Grippotyphosa</td>
<td>Moskva V</td>
<td>India</td>
</tr>
<tr>
<td>AAT48501.1</td>
<td>Grippotyphosa</td>
<td>Lin 6</td>
<td>China</td>
</tr>
<tr>
<td>AHX26959.1</td>
<td>Grippotyphosa</td>
<td>RTCC 2808</td>
<td>Iran</td>
</tr>
</tbody>
</table>
Protein purification and immunoblotting. The rLip41 protein was purified from the post sonication pellets under denaturation conditions using serial concentrations of 1 to 8M urea in PBS buffer at 37 °C. The post sonication pellets were suspended in 5 mL 1M urea and shacked for 1h in 37 °C. Washing with 2 to 5 M urea was done for 1 hour, and the 6 to 8 M concentrations of urea were incubated overnight. Purified proteins were dialyzed in 1X PBS and assessed by 10% SDS-PAGE, then stored at -70 °C for further analysis.

Western blotting was performed. The blocking step was performed by 1% BSA in PBS containing 0.1% Tween 20, then probed with a HRP conjugated anti-6x His-Tag antibodies (Abcam, USA) (diluted 1:5,000). 4-choloro-1-naphthol was used for developing the protein band.

Protein assay. Quantitation of recombinant protein was performed by Bradford protein assay. To achieve a standard curve, various concentrations of 0.25 mg/mL BSA (Bovine Serum Albumin) were utilized. Ten dilutions of BSA were prepared in range of 0 to 10 µg/µL protein as a standard lane in deionized water. 200 µL Bradford reagent was added to all dilutions containing BSA and recombinant protein up to 1 mL final volume.

Results

Phylogenetic analysis of full length LipL41 proteins (355aa) showed 0.8 percent divergence between six serovars of *leptospira interrogans* in Iran and the other countries (as shown in Fig. 1). Multiple Alignment of LipL41 protein sequences using MegAlign software identified significant amino acid substitutions had taken place among the serovars. Notably, 20 different amino acid substitutions were detected, 8 of which were observed among some Iranian isolates, as stipulated below: in Iranian *Leptospira* serovar Grippothyphosa (AHW80388.1) and (AHX26959.1) isolates, 3 amino acid substitutions were found in residues 146, 212 and 312 (I146→ V146, F212→ Y212 and T312→A312). Furthermore, in serovar Pomona (AHW80385.1) and serovar Hardjo (AHX26962.1) one amino acid substitution was observed in residue 204 (V204→ I204). On the basis of these polymorphisms, the local Lipl41 protein pattern was used to design the construct.

Fig. 1. Phylogenetic analysis of six *leptospira interrogans* serovars, including eleven from Iran and sixteen from other countries submitted to GenBank (protein Id). The phylogenetic tree based on LipL41 protein sequences used Megalign software.

Fig. 2. SDS-PAGE (12%) analysis of the expressed rLip41 protein in BL21 (DE3) which was induced by 0.1mM IPTG at different times. Lane 1: Unstained protein molecular weight marker (kDa), (Thermo, scientific). Lane2: non-induced cell lysate. Lane 3: induced (1h) cell lysate. Lane 4: induced (3h) cell lysate. Lane 5: induced (4h) cell lysate. Lane 6: induced (over-night) cell lysate.

Recombinant protein was induced at different times, temperatures and various concentrations of IPTG. The protein electrophoresis by SDS-PAGE analysis revealed a distinct band that corresponded to successful induction of full-length 47 kDa LipL41 protein. However, maximum expression of the Lipl41 recombinant protein was observed at 4 h
post induction incubation at 37 °C in the presence of 0.1 mM IPTG (Fig. 2).

Analysis of the cell lysate post-sonication demonstrated that the recombinant protein was mostly found in the pellet, not in the supernatant.

The protein was purified after washing in serial concentrations of urea in PBS (1 to 5M) and then solubilized in (6 to 8M) at 37 °C. The results of protein purification in all three concentrations of urea (6 to 8M) showed a sharp single band (at 47 KDa). Moreover, the protein obtained from purification with an urea concentration of 6M had the maximum protein concentration (Fig. 3). The yield of purified recombinant protein was estimated to be 28.3 mg/mL.

Western blot confirmed the distinct 47 kDa band (Fig. 4).

**Discussion**

In recent years many studies have been conducted on the identification, expression, and characterization of the leptospiral OMPs, such as OmpL1, Omp52, LipL21, LipL36, LipL41, etc (HAAKE and MATSUNAGA, 2002; SENTHILKUMAR et al., 2007; DEZHBORD et al., 2014; HOSEINPUR et al., 2015; SOLTANI et al., 2015). Some other studies revealed that, unlike leptospiral LPS, OMPs are generally well conserved, not serovar specific and able to induce cross-protective immunity (KOIZUMI and WATANABE, 2005; OLIVEIRA et al., 2015). In addition, leptospiral OMPs are commonly exposed on the surface and are among the first antigens that interact with host immune cells (CULLEN et al., 2002; NALLY et al., 2007).

One of the most important OMPs expressed during human infection is LipL41, a 41kDa lipoprotein that is highly conserved in pathogenic *Leptospira* species. (MEGUDESWARAN et al., 2014) Furthermore, LipL41 has been determined as a hemin-binding protein (LIN et al., 2013), and is one of the key virulence factors involved in host-pathogen contact. Thus, it appears that LipL41 may play an important role in inducing immunological responses in the host (GUERREIRO et al., 2001).

According to previous reports, the use of LipL41 of pathogenic *Leptospira* in a multi-serovar ELISA enhanced the sensitivity of the test (THEODORIDIS et al., 2005; NATARAJASEENIVASAN et al., 2008). Another investigation conducted by MARIYA et al in 2006 demonstrated that LipL41 antigen in ELISA...
is a possible candidate for serodiagnosis of bovine leptospiral infection. Moreover, earlier studies indicated that this protein is expressed throughout acute infection (KING et al., 2013), and may be susceptible to the host immune defenses, either by itself or in combination with OmpL1 (HAAKE et al., 1999; LIN et al., 2011).

Consequently, Lipl41 could be considered a genus-specific antigen for improvement of new broad spectrum vaccines and serodiagnostic techniques against leptospirosis.

Therefore, our study focused on the expression and purification of Lipl41 protein of Iranian pathogenic *Leptospira* in *E. coli*. We used BLAST software to gather all the protein sequences of Lipl41 of pathogenic *Leptospira* from different serovars from Iran and other countries available in the NCBI database. A significant finding in our study was the detection of 8 amino acid substitutions in some Iranian isolates, which, to our knowledge, have not been reported in the literature. Gene construct was then designed according the pattern of local Lipl41 protein prevalent pathogenic *Leptospira* isolates.

Induction of the recombinant protein using various concentrations of IPTG was performed at different times and temperatures, which demonstrated the maximum expression of Lipl41 recombinant protein in BL21 (DE3) at 37 °C and 0.1mM IPTG at 4 hours post induction. A high level of expression of Lipl41 was observed (28.38 mg/mL). Hence, under these conditions, optimal recombinant protein purification was achieved as one distinct band, with an approximate molecular weight of 47kDa. On the basis of our results, the blotted protein (using HRP-conjugated Anti-6x His-Tag Ab) verified the presence of the recombinant Lipl41 protein as illustrated in Fig. 4.

Some researchers have obtained high expression rates of this protein using either pET series (MEGUDESWARAN et al., 2014; LIN et al., 2016) or other similar expression vectors (MARIYA et al., 2006; KING et al., 2013; LIN et al., 2013). Solubility is an important factor for producing recombinant proteins in heterologous expression systems. Due to differences in folding structure, soluble recombinant proteins are usually considerably easier to purify compared with insoluble ones (COSTA et al., 2014). Despite the use of the TRX tag sequence during gene construction to enhance solubility, a significant amount of the recombinant protein was found in the inclusion body, while lesser quantities were detected in the supernatant, and expressed in the insoluble form. These results agreed with other studies where the over expressed Lipl41 was observed mostly in the inclusion body, and purified under denaturing conditions (MARIYA et al., 2006; KING et al., 2013; LIN et al., 2013). Although in one report this protein was solubilized with 6M guanidine, (HAAKE et al., 1999), in this study we used 1-8 M urea according to the manual protocol (to be under published). This provided an efficient and cost-effective method which is applicable for purification of Lipl41 insoluble proteins.

**Conclusion**

In conclusion, this study demonstrated 0.8 percent divergence between Lipl41 protein sequences of Iranian and foreign *Leptospira interrogans* serovars. 8 amino acid substitutions were identified among local serovars which were used to design the gene construct. It was successfully expressed in *E. coli* BL 21(DE3) and purified by denaturation, using serial concentrations of urea.

The presence of purified protein was confirmed with SDS-PAGE analysis and western blotting.

Therefore, the possible immunogenicity of this recombinant protein was demonstrated, and it may have the potential to induce effective protective immunity against leptospirosis in the future. However, the serodiagnostic ability of this recombinant protein as a capture antigen in the ELISA method in animal and human subjects requires further investigation.

**Acknowledgements**

This study was supported by a grant (Number: 12-18-18-106-96045-961023) from Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

**References**


DOI: 10.3855/jidc.8067


DOI: 10.1128/IAI.73.8.4853-4863


DOI: 10.1128/IAI.69.8.4958-4968.2001


DOI: 10.1128/IAI.69.8.4958-4968.2001


Vet. arhiv 90 (3), 297-305, 2020
DOI: 10.1016/S0891-5520(05)70216-6

DOI: 10.1097/01.qco.0000178824.05715.2c

DOI: 10.1016/j.cimid.2006.06.007


DOI: 10.1128/IAI.00511-08

DOI: 10.1128/IAI.00741-06

DOI: 10.1179/136485908X355229

DOI: 10.1371/journal.pone.0142821


DOI: 10.3201/eid0809.010499


DOI: 10.7508/ari.2015.03.001

DOI: 10.1093/infdis/jiq127


DOI: 10.1016/S1672-0229(08)60038-8

DOI: 10.1016/j.meegid.2010.01.001
Expression and purification of the Lipl41, a surface–exposed lipoprotein antigen of pathogenic *Leptospira* spp.

Received: 31 August 2019
Accepted: 21 May 2020


SAŽETAK

Patogene vrste *Leptospira* uzrokuju zoonotsku bolest leptospirozu koja je raširena u cijelom svijetu. Cilj istraživanja bio je dokazati antigeone koji potiču imunosni odgovor i mogu se primijeniti u dijagnostičkim kompletima ili za razvoj cjepiva. Vanjska proteinska membrana (OMPs) leptospira potencijalni je kandidat za tu svrhu, a gen Lipl41 je dobro očuvan među patogenim leptospirama. Ekspresija i pročišćavanje rekombinantnog proteina Lipl41 provedeno je u izolatima iz Irana. Uspoređene su sve prikupljene sekvencije proteina Lipl41 i analizirane bioinformatičkim alatom iz baze podataka NCBI. Kompletne sekvencije kodona rekombinantnog proteina Lipl41 u izolatima su optimizirane, zatim subklonirane u pET32a+ vektor i pretvorene u bakteriju *Escherichia coli* BL21 (DE3). Optimalna ekspresija rekombinantnog Lipl41 (47kDa) postignuta je post-indukcijski pomoću isopropyl β-d-1-thiogalactopyranoside (IPTG). Zatim je pročišćena denaturacijom što je uključilo primjenu serijskih koncentracija ureje. Rekombinantni protein je potvrđen metodom western blot. Istraživanje potvrđuje mogućnost ostvarenja dostatne količine i ekspresije pročišćenog Lipl41 da se može upotrijebiti za razvoj dijagnostičkih kompleta i subjediničnih cjepiva.

**Ključne riječi:** rekombinirani protein Lipl41; ekspresija; pročišćavanje; patogena *Leptospira*.